Development and assessment of targeted radionuclide combined with death inducing and growth inhibiting immunotherapy for potential treatment of hormone refractory prostate cancer (HRPC).
Ahuva Nissim and Steve Mather, Barts and the London School of Medicine

Isolation, culture and molecular characterisation of castration refractory prostate cancer (CRPC) stem cells from clinical tumour material.
Dr David Hudson, Insitute of Cancer Research, then University of York

Importance of Interleukin-8 signalling as a mode of resistance of prostate cancer cells to Ionizing Radiation.
Dr David Waugh, Queen's University, Belfast

Endogemous anti-angiogenic tumour suppressing VEGF splice variants in the treatment of prostate cancer.
Dr Steven Harper, David Gillatt & Dr Dave Bates, Bristol Urological Institute

A gene therapy strategy for metastastic prostate cancer: use of a novel molecular switch for transcriptional targeting of iNOS.
Prof David Hirst, Dr Tracy Robson & Dr Helen McCarthy, School of Pharmacy, Queen's University, Belfast 

Development of oncolytic adenoviruses for targeting of androgen-independent prostate cancers: enhancement of anti-tumour efficacy by combination therapies.
Gunnel Halldén, Queen Mary, University of London

Investigation of environmental, lifestyle and genetic risk factors for prostate cancer in younger men.
Prof Kenneth Muir, University of Nottingham

PCRF Clinical Research Fellowship 'Prostate Cancer Proliferative Cell Markers'.
Hide Yamamoto & Prof John Masters, Prostate Cancer Research Centre